Back to search results

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Adenocarcinoma · Esophageal Squamous Cell Carcinoma · Gastroesophageal Junction Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States

    Contact: Study coordinator (Albert Lin, MD) · albert.lin6@va.gov · 650-493-5000

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Laura A Randolph, BA) · Laura.Randolph@va.gov · 734-845-5091
    Contact: Principal Investigator (David H Wang, MD PhD)

  • Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

    Contact: Study coordinator (Michael Kelley, MD) · michael.kelley6@va.gov · 919-286-0411

  • VA Portland Health Care System, Portland, OR, Portland, Oregon, United States

    Contact: Study coordinator (Kenneth Bensch, MD) · kenneth.bensch1@va.gov · 503-220-8262

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States

    Contact: Study coordinator (Nicole Pore-Brown) · Florine.Pore-Brown@va.gov · 214-857-3291

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States

    Contact: Study coordinator (Yvonne Sada, MD) · yvonne.sada@va.gov · 713-794-7454

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States

    Contact: Study coordinator (Daniel Wu, MD) · daniel.wu@va.gov · 206-764-2182
Study leads

  • David H Wang, MD PhD

    Principal Investigator

    VA Ann Arbor Healthcare System, Ann Arbor, MI

View source on ClinicalTrials.gov(opens in a new tab)